SCHEMBL6609906

SCHEMBL6609906

NCC(Cc1ccccc1)C(N)=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.61
EPHX1 P07099 1/20 0.56
CPA1 P15085 6/20 0.53
CPA3 P15088 3/20 0.53
FOLH1 Q04609 2/20 0.53
CPB1 P15086 1/20 0.53
CPB2 Q96IY4 1/20 0.53
SLC1A3 P43003 1/20 0.53
SLC1A2 P43004 1/20 0.53
SLC1A1 P43005 1/20 0.53
ALPI P09923 1/20 0.52
PKM P14618 1/20 0.52
PTGS1 P23219 1/20 0.52
XIAP P98170 1/20 0.52
SLC7A5 Q01650 1/20 0.52
ANPEP P15144 1/20 0.51
ERAP2 Q6P179 1/20 0.51
ALDH1A1 P00352 1/20 0.47
POLB P06746 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7353741 1.00 CYP1A2 (0.61) CYP1A2EPHX1CPA1CPA3FOLH1
SCHEMBL19532713 1.00 CYP1A2 (0.61) CYP1A2EPHX1CPA1CPA3FOLH1
SCHEMBL27310677 0.93 CYP1A2 (0.53) CYP1A2EPHX1CPA1CPA3FOLH1
SCHEMBL7403760 0.93 CYP1A2 (0.53) CYP1A2EPHX1CPA1CPA3FOLH1
SCHEMBL27318657 0.93 CYP1A2 (0.53) CYP1A2EPHX1CPA1CPA3FOLH1
SCHEMBL5052372 0.90 CYP1A2 (0.68) CYP1A2EPHX1CPA1CPA3FOLH1
Hydrochloric Acid SCHEMBL27320070 0.86 EPHX1 (0.47) CYP1A2EPHX1CPA1CPA3FOLH1
SCHEMBL4738634 0.86 CYP1A2 (0.76) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL558159 0.86 CYP1A2 (0.76) CYP1A2CPA1CPA3FOLH1CPB1
SCHEMBL5171909 0.86 CYP1A2 (0.76) CYP1A2CPA1CPA3FOLH1CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023078410-A1 COMPOUND HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF 上海美志医药科技有限公司 2023-05-11 WO disclosed
US-6818655-B2 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM CORPORATION 2004-11-16 US disclosed
EP-1359915-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM (US) 2004-07-21 EP disclosed
US-20040063757-A1 Urotensin-ll receptor antagonists SMITHKLINEE BEECHAM CORPORATION 2004-04-01 US disclosed
EP-1359915-A1 UROTENSIN-II RECEPTOR ANTAGONISTS Smithkline Beecham (US) 2003-11-12 EP disclosed
WO-2002058702-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (GB) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063757-A1 Urotensin-ll receptor antagonists UTS2R, PLAUR, SCTR CYP1A2 3105/4885EPHX1 1353/4885CPA1 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.